Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 1,230.7% in February

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 389,900 shares, a growth of 1,230.7% from the February 13th total of 29,300 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average trading volume of 336,300 shares, the short-interest ratio is presently 1.2 days.

Institutional Investors Weigh In On Chemomab Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of Chemomab Therapeutics in the 4th quarter valued at about $26,000. XTX Topco Ltd raised its position in shares of Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after acquiring an additional 9,706 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Chemomab Therapeutics in the 3rd quarter valued at approximately $1,907,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Down 1.1 %

Shares of NASDAQ:CMMB opened at $1.38 on Friday. Chemomab Therapeutics has a 12 month low of $0.58 and a 12 month high of $2.55. The company’s 50-day moving average price is $1.88 and its two-hundred day moving average price is $1.74. The firm has a market cap of $19.74 million, a P/E ratio of -1.37 and a beta of 0.54.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $11.00 price objective (down from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th. Maxim Group increased their price objective on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, February 20th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).